Jefferies Starts Ascendis Pharma (ASND) at Buy, 'A PaTH of Growth, ApproaCHing Success, All with TransCon'
Tweet Send to a Friend
(Updated - December 20, 2023 4:52 AM EST)
Jefferies analyst Kelly Shi initiates coverage on Ascendis Pharma (NASDAQ: ASND) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Jefferies analyst Kelly Shi initiates coverage on Ascendis Pharma (NASDAQ: ASND) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
